Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 453-458

  Devitt, Bianca ^a   McLachlan, Sue Anne ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Bone metastasis; Breast cancer; Ibandronate; Oral bisphosphonate; Skeletal complications

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; LORON; OPIATE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTHRALGIA; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMOTION; ESOPHAGITIS; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PHYSICAL ACTIVITY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOCIAL STATUS; SPINAL CORD COMPRESSION; TREATMENT DURATION;

EID: 44049105496     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Ali SM, Esteva FJ, Hortobagyi G, et al. 2001. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol, 19:3434-7.
2. Atula S, Powles, T Paterson A, et al. 2003. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf, 26:661-71.
3. Bamias A, Kastritis, E Bamia C, et al. 2005. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol, 23:8580-7.
4. Banerjee D, Asif A, Striker L, et al. 2003. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis, 41:E18.
5. Bergstrom B, Lichinitser M, Body JJ. 2006. Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase II/III trials. Bone, 38(Suppl 1):S68.
6. Body JJ, Diel IJ, Bell R, et al. 2004. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain, 111:306-12.
7. Body JJ, Diel IJ, Lichinitser MR, et al. 2003a. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol, 14:1399-405.
8. Body JJ, Diel IJ, Lichinitzer M, et al. 2004. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer, 90:1133-7.
9. Body JJ, Kanis J, Diel I, et al. 2003b. Risk reductions in metastatic breast cancer: mulitvariate Poisson regression analyes of oral and i.v. ibandroante. Am Soc Clin Oncol, 22:46.
10. Body JJ, Lichinister M, Tjulandin S, et al. 2006. Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data. Bone, 38(Suppl 1):S69.
11. Body JJ, Lichinitser M, Tjulandin S, et al. 2007. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol, 18:1165-71.
12. Body JJ, Louviaux I, Dumon JC. 2000. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer, 8:398-404.
13. Chang JT, Green L, Beitz J. 2003. Renal failure with the use of zoledronic acid. N Engl J Med, 349:1676-9; discussion 1676-9.
14. Clemons M, Dranitsaris G, Ooi W, et al. 2008. A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat, 108:79-85.
15. Coleman RE. 2001. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 27:165-76.
16. Daubine F, Le Gall C, Gasser J, et al. 2007. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst, 99:322-30.
17. De Cock E, Hutton J, Canney P, et al. 2005. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer, 13:975-86.
18. Diel IJ, Body JJ, Lichinitser MR, et al. 2004. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer, 40:1704-12.
19. Diel IJ, Solomayer EF, Bastert G. 2000. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer, 1:43-51.
20. Durie BG, Katz M, Crowley J. 2005. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med, 353:99-102.
21. Grano M, Mori G, Minielli V, et al. 2000. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem Biophys Res Commun, 270:1097-100.
22. Hillner BE, Ingle JN, Chlebowski RT, et al. 2003. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol, 21:4042-57.
23. Hiraga T, Williams PJ, Mundy GR, et al. 2001. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res, 61:4418-24.
24. Hortobagyi GN, Theriault RL, Lipton A, et al. 1998. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol, 16:2038-44.
25. Hultborn R, Gundersen S, Ryden S, et al. 1999. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res, 19:3383-92.
26. Lipton A. 2003. Bone metastases in breast cancer. Curr Treat Options Oncol, 4:151-8.
27. Liu G, Franssen E, Fitch MI, et al. 1997. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol, 15:110-5.
28. Luckman SP, Hughes DE, Coxon FP, et al. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res, 13:581-9.
29. Major PP, Lipton A, Berenson J, et al. 2000. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 88:6-14.
30. Malden NJ, Pai AY. 2007. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J, 203:93-7.
31. Mancini I, Dumon JC, Body JJ. 2004. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol, 22:3587-92.
32. Mavrokokki T, Cheng A, Stein B, et al. 2007. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg, 65:415-23.
33. McLachlan SA, Cameron D, Murray R, et al. 2006. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig, 26:43-8.
34. Michigami T, Hiraga T, Williams PJ, et al. 2002. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat, 75:249-58.
35. Monkkonen H, Auriola S, Lehenkari P, et al. 2006. A new endogenous ATP analog (Apppl) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol, 147:437-45.
36. Navarro RP, Morrow T, Baran R. 2002. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface, 15:55-62.
37. Nobuyuki H, Hiraga T, Williams PJ, et al. 2001. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res, 16(Suppl 1):S191.
38. NovartisPharma. Aredia (pamidronate). Prescribing information. NovartisPharma. Zometa (zoledronic acid). Prescribing Information.
39. Oliff A. 1999. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim Biophys Acta, 1423:C19-30.
40. Paley M, Love N, Carlson R, et al. 2005. Preferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. Proc Am Soc Clin Oncol, 23:619.
41. Paterson AH, Powles TJ, Kanis JA, et al. 1993. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol, 11:59-65.
42. Pavlakis N, Stockler M. 2002. Bisphosphonates for breast cancer. Cochrane Database Syst Rev,(1): CD003474.
43. Pazianas M, Blumentals WA, Miller PD. 2007. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int. Nov 13 [Epub ahead of print].
44. Pecherstorfer M, Rivkin S, Body JJ, et al. 2006. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig, 26:315-22.
45. Pfeilschifter J, Mundy GR. 1987. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA, 84:2024-8.
46. Powles T, Paterson S, Kanis JA, et al. 2002. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol, 20:3219-24.
47. Rosen LS, Gordon D, Kaminski M, et al. 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7:377-87.
48. Russell RG, Croucher PI, MJ. Rogers 1999. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int, 9(Suppl 2): S66-80.
49. Russell RG, Rogers MJ, Frith JC, et al. 1999. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res, 14(Suppl 2):53-65.
50. Szeto CC, Chow KM. 2005. Nephrotoxicity related to new therapeutic compounds. Ren Fail, 27:329-33.
51. Tripathy D, Lichinitzer M, Lazarev A, et al. 2004. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol, 15:743-50.
52. Zhang FL, Casey PJ. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem, 65:241-69.